Article2025
Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Sohyun Hwang, Dong Jun Shin, Beodeul Kang, Haeyoun Kang, Sung Hwan Lee, Jung Sun Kim, Je‐Gun Joung, Suyog Jain, Steven R. Olsen, Lars Becker, Richard S. Finn, Josep M. Llovet, Gwangil Kim, Chan Kim, Hong Jae Chon Article2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka,
Article2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Jaekyung Cheon, Naoshi Nishida, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein,
Article2025
No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study
Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Masahiro Takita, Hirokazu Chishina, M Morita, Tomoko Aoki, Tetsutaro Hamano, R. Take, Chizuko Watanabe, Kentaro Asoh, Ai Tanaka, Masatoshi Kudo Article2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada,
Discussion(0)
No comments yet. Be the first to comment.